Ekso Bionics to Report Second Quarter 2025 Financial Results on July 28 – Conference Call to Follow
Rhea-AI Summary
Ekso Bionics (NASDAQ:EKSO), a leader in medical and industrial exoskeleton technology, has scheduled its Q2 2025 financial results release for July 28, 2025 after market close. The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss financial performance and recent business developments.
Investors can join via phone by dialing 877-407-6184 (domestic) or 201-389-0877 (international). The presentation will also be available through a live webcast and archived on the company's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, EKSO declined 2.53%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.2% during that session. Argus tracked a trough of -2.9% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $261K from the company's valuation, bringing the market cap to $10M at that time.
Data tracked by StockTitan Argus on the day of publication.
SAN RAFAEL, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter of 2025 after the close of trading on Monday, July 28, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments.
To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company’s website at www.eksobionics.com under “Presentations & Events” in the Investors section.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com.
Contact:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@eksobionics.com
FAQ
When will Ekso Bionics (EKSO) release Q2 2025 earnings?
What time is the Ekso Bionics Q2 2025 earnings call?
How can I listen to Ekso Bionics (EKSO) Q2 2025 earnings call?
Where can I find the replay of Ekso Bionics Q2 2025 earnings call?
